Subscribe To

Price Alert Latest News Economic Calendar News

BAYRY / Bayer Aktiengesellschaft (BAYZF) CEO Werner Baumann on Q1 2022 Results - Earnings Call Transcript

Bayer Aktiengesellschaft (OTCPK:BAYZF) Q1 2022 Results Conference Call May 10, 2022 8:00 AM ET Company Participants Oliver Maier - Head, IR Werner Baumann - CEO Wolfgang Nickl - CFO Rodrigo Santos - President, the Crop Science Division Stefan Oelrich - Head, the Pharmaceuticals Division Conference Call Participants Vincent Andrews - Morgan Stanley Pete Verdult - Citigroup Sachin Jain - Bank of America Michael Leuchten - UBS James Quigley - Morgan Stanley Keyur Parekh - Goldman Sachs Falko Friedrich - Deutsche Bank Christian Faitz - Kepler Cheuvreux Steve Byrne - Bank of America Richard Vosser - JPMorgan Operator Ladies and gentlemen, thank you for standing by. Welcome to Bayer's Investor and Analyst Conference Call on the First Quarter 2022 Results. Read More

Demo Live Account See Partner Details

Content Topics

Bayer

Aktiengesellschaft

Bayzf

Werner

Baumann

2022

Results

bayzf

Earnings

Transcript

Stock

BAYRY

Posted: May 10 2022, 12:57

Author Name: Seeking Alpha

BAYRY News

By Reuters
October 31, 2023

Bayer ordered to pay $332 mln in Roundup cancer trial -Law.com

A California jury found Bayer liable in a case brought by a man who claimed his cancer was due to exposure to the company's Roundup weed killer, and o

By Zacks Investment Research
October 17, 2023

New Strong Sell Stocks for October 17th

BAYYR, EDAP and FWRD have been added to the Zacks Rank #5 (Strong Sell) List on October 17, 2023.

By Yahoo Finance
October 15, 2023

Gene therapy, Parkinson's disease, and food science: Bayer U.S. discusses the latest technology

Most Americans know Bayer (BAYN.DE) for its over-the-counter medicines like Aleve and Claritin. But that's not all the company does.

By Zacks Investment Research
October 6, 2023

Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery

Bayer (BAYRY) collaborates with Twist Bioscience to advance breakthrough innovations based on new scientific approaches and platform technologies.

By Market Watch
September 12, 2023

Key drug in Sudafed, Dayquil and many other decongestants doesn't relieve congestion: FDA

WASHINGTON (AP) — The leading decongestant used by millions of Americans looking for relief from a stuffy nose is no better than a dummy pill, accor

By Reuters
August 28, 2023

Bayer says Parkinson's stem cell therapy improves symptoms in initial trial

Bayer said an experimental stem cell therapy developed by its U.S. subsidiary BlueRock had shown signs of easing Parkinson's disease symptoms in an ea

By Seeking Alpha
August 22, 2023

Bayer: Still A Strong Buy Despite Lowered Guidance

Bayer reporting disappointing second quarter results with declining sales and lowered the guidance for fiscal 2023. The company is continuing to strug

By Seeking Alpha
August 8, 2023

Bayer Aktiengesellschaft (BAYZF) Q2 2023 Earnings Call Transcript

Bayer Aktiengesellschaft (OTCPK:BAYZF) Q2 2023 Earnings Call Transcript August 8, 2023 8:00 AM ET Company Participants Oliver Maier - Head of IR Bill

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.